Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. INDV
INDV logo

INDV Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Indivior Pharmaceuticals, Inc (INDV) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Buy
Latest Price
36.990
1 Day change
1.23%
52 Week Range
41.000
Analysis Updated At
2026/05/15
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

INDV is a buy for a beginner long-term investor with $50,000-$100,000 available. The stock has supportive fundamentals from strong Q1 revenue growth, a meaningful jump in Sublocade sales, and aggressive share repurchases, while the news flow is constructive. Technically, the trend is still bullish despite a mild pre-market dip, and the current price is sitting near support. Options sentiment is clearly bullish. Since there is no AI Stock Picker or SwingMax signal today, the decision rests on the broader setup, which is favorable enough to buy now rather than wait.

Technical Analysis

INDV is in a constructive uptrend. SMA_5 is above SMA_20, which is above SMA_200, confirming bullish medium- and long-term structure. MACD histogram is slightly positive at 0.00676 but contracting, showing momentum is still positive though not accelerating. RSI_6 at 48.31 is neutral, so the stock is not overbought. Pre-market price is 37.5, close to S1 support at 37.504 and below pivot at 39.001, which makes this an acceptable entry zone for a long-term buyer. The near-term pattern data is mixed, with only modest short-term upside expected, but the broader trend remains favorable.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is strongly bullish. Both put-call ratios are very low, showing call-heavy positioning and limited downside hedging demand. Call open interest (23,507) far exceeds put open interest (4,559), and today's options activity is elevated versus average, suggesting active speculative interest. Implied volatility at 59.39 is elevated, but IV rank 14.31 and IV percentile 36.9 suggest volatility is not unusually expensive relative to recent history. Overall, options data supports a bullish outlook.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
3
Buy
8

Positive Catalysts

  • ["Q1 revenue increased 19% year over year to $317 million", "Sublocade sales rose 32% to $232 million, showing strong product momentum", "Claret Asset Management bought 707,267 shares worth $23.36 million, a meaningful new institutional position", "Company repurchased about 4 million shares and announced a $175 million accelerated share repurchase program", "Technical trend remains bullish with SMA_5 > SMA_20 > SMA_200", "Options positioning is strongly bullish with low put-call ratios"]

Neutral/Negative Catalysts

  • ["Pre-market price is down 0.87%, showing slight near-term weakness", "MACD histogram is positive but contracting, so momentum is not strengthening", "RSI is neutral, indicating the stock is not in a strong breakout phase", "No recent AI Stock Picker or SwingMax signal", "No recent congress trading data available"]

Financial Performance

Latest quarter: Q1. Indivior reported revenue growth of 19% year over year to $317 million, which is a strong top-line expansion. The main growth driver was Sublocade, whose sales increased 32% to $232 million. That combination points to solid operating momentum in the latest quarter and supports a positive long-term growth view.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No direct analyst rating or price target change data was provided. Based on the available Wall Street-style evidence, the pros case is stronger than the cons: revenue growth is solid, key product sales are accelerating, and capital return via buybacks is aggressive. The bearish side is limited to muted short-term technical momentum and no fresh analyst upgrade/downgrade trend in the data.

Wall Street analysts forecast INDV stock price to rise
5 Analyst Rating
Wall Street analysts forecast INDV stock price to rise
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 36.540
sliders
Low
36
Averages
43.75
High
50
Current: 36.540
sliders
Low
36
Averages
43.75
High
50
Northland
Outperform
upgrade
$40 -> $50
AI Analysis
2026-01-20
Reason
Northland
Price Target
$40 -> $50
AI Analysis
2026-01-20
upgrade
Outperform
Reason
Northland raised the firm's price target on Indivior to $50 from $40 and keeps an Outperform rating on the shares. With legacy overhangs resolved, and capital allocation optionally emerging, the firm views the current valuation as "disconnected from underlying fundamentals" as it raises its FY26 revenue and adjusted EPS estimates.
Morgan Stanley
Overweight
maintain
$28 -> $36
2025-12-03
Reason
Morgan Stanley
Price Target
$28 -> $36
2025-12-03
maintain
Overweight
Reason
Morgan Stanley raised the firm's price target on Indivior to $36 from $28 and keeps an Overweight rating on the shares. The firm sees the EU Pharmaceuticals sector set up as neutral into 2026, with fundamentals intact at a low valuation premium compared to history, offset by better EPS growth elsewhere in Europe, the analyst tells investors in a year-ahead outlook note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for INDV
Unlock Now

People Also Watch